Amphotericin B lipid complex: treatment of invasive fungal infections | TCRM
Amphotericin B lipid complex: treatment of invasive fungal infections in patients refractory to or intolerant of amphotericin B deoxycholate PH ChandrasekarDivision of Infectious Diseases, Department of Internal Medicine, Wayne State University, Karmanos Cancer Institute, Detroit, MI, USAAbstract: Amphotericin B lipid complex (ABLC) was introduced in the late 1990s as a less toxic alternative to amphotericin B (AmB) deoxycholate. ABLC is a safe and effective broad-spectrum drug in the treatment of invasive fungal infections in patients with infection refractory to AmB deoxycholate or in patients intolerant of the same formulation. The drug has not been rigorously evaluated for primary therapy. Recent availability of several newer potent and safe drugs has sharply curtailed the use of potentially nephrotoxic ABLC. However, AmB lipid complex is likely to ...https://www.dovepress.com/amphotericin-b-lipid-complex-treatment-of-invasive-fungal-infections-i-peer-reviewed-article-TCRM-recommendation1
Mortality and Costs of Acute Renal Failure Associated with Amphotericin B Therapy : Clinical Infectious Diseases - oi
To assess the mortality and resource utilization that results from acute renal failure associated with amphotericin B therapy, 707 adult admissions in which parenteral amphotericin B therapy was given were studied at a tertiary-care hospital. Main outcome measures were mortality, length of stay, and costs; we controlled for potential confounders, including age, sex, insurance status, baseline creatinine level, length of stay before beginning amphotericin B therapy, and severity of illness. Among 707 admissions, there were 212 episodes (30%) of acute renal failure. When renal failure developed, the mortality rate was much higher: 54% versus 16% (adjusted odds of death, 6.6). When acute renal failure occurred, the mean adjusted increase in length of stay was 8.2 days, and the adjusted total cost was $29,823. Although residual confounding exists despite adjustment, the increases in resource utilization that we ...http://oxfordindex.oup.com/view/10.1086/319211
METHODS AND FORMULATIONS FOR REDUCING AMPHOTERICIN B TREATMENT SIDE EFFECTS - Patent application
0196] Throughout this application, various publications are referenced, specifically including those listed below. All such references are incorporated herein by reference.  Brajtburg, J., W. G. Powderly, G. S. Kobayashi and G. Medoff. 1990. Amphotericin B: current understanding of mechanisms of action. Antimicrob Agents Chemother. 34:183-188.  Cagnoni, P. J., T. J. Walsh, M. M. Prendergast, D. Bodensteiner, S. Hiemenz, R. N. Greenberg, C. A. Arndt, M. Schuster, N. Seibel, V. Yeldandi, and K. B. Tong. 2000. Pharmacoeconomic analysis of liposomal amphotericin B versus conventional amphotericin B in the empirical treatment of persistently febrile neutropenic patients. J. Clin. Oncol. 18(12):2476-83.  Chavanet, P., V. Joly, D. Rigaud, J. Bolard, C. Carbon, P. Yeni. Influence of diet on experimental toxicity of amphotericin B deoxycholate. Antimicrob. Agents ...http://www.patentsencyclopedia.com/app/20110152211
Comparison of Fluconazole and Amphotericin B in the Treatment of Brain Infections in Patients With AIDS - Full Text View -...
Cryptococcal meningitis is a life-threatening infectious complication of AIDS. Because relapse after treatment occurs in over 50 percent of cases, chronic maintenance therapy with intravenous (IV) amphotericin B is usually given. However, amphotericin B is not always effective, has toxic effects, and must be given by the intravenous route. Fluconazole is an antifungal agent that can be given orally and has been shown to be effective against cryptococcal infections in animals and against acute CM in a few AIDS patients. Also, the side effects experienced by over 2000 patients or volunteers given fluconazole have seldom been severe enough to require withdrawal of the drug.. Patients accepted in the trial are randomly assigned to fluconazole or amphotericin B. Fluconazole is given orally once a day and amphotericin B is given intravenously once a week. Dosages depend on body ...https://clinicaltrials.gov/show/NCT00001017?order=23
Efficacies of High-Dose Fluconazole plus Amphotericin B and Hi...
Efficacies of High-Dose Fluconazole plus Amphotericin B and High-Dose Fluconazole plus 5-Fluorocytosine versus Amphotericin B, Fluconazole, and 5-Fluorocytosinehttps://www.mysciencework.com/publication/show/efficacies-of-high-dose-fluconazole-plus-amphotericin-b-and-high-dose-fluconazole-plus-5-fluorocytosine-versus-amphotericin-b-fluconazole-and-5-fluorocytosine-monotherapies-in-treatment-of-experimental-endocarditis-endophthalmitis-and-pyelonephritis-due-to-candida-albicans
Alternatives to amphotericin B for Candida rugosa infection
Objective: Amphotericin B failure is frequently seen in patients with candidaemia caused by Candida rugosa. We evaluated amphotericin 13, fluconazole, posaconazole and voriconazole as alternative treatments against infection in mice with two isolates of C. rugosa.Methods: Neutropenic mice were inoculated intravenously with C. rugosa. Amphotericin 13, fluconazole, posaconazole and voriconazole were administered for 7 days after infection. Efficacy of the antifungal treatment was assessed by survival and tissue burden of C. rugosa.Results: All of the four drugs significantly prolonged survival over controls. With both isolates, kidney counts were reduced significantly below controls for amphotericin B, fluconazole and posaconazole. However, voriconazole was less effective than the other antifungals.Conclusion: Despite poor clinical response to ...http://repositorio.unifesp.br/handle/11600/27842
Amphotericin B Treatment for Indian Visceral Leishmaniasis: Response to 15 Daily versus Alternate-Day Infusions : Clinical...
Background. For patients with Indian visceral leishmaniasis, amphotericin B deoxycholate is usually given as 15 alternate-day infusions of 1 mg/kg over 30 days (total dose, 15 mg/kg); daily treatment with 1 mg/kg for 20 days (total dose, 20 mg/kg) is also used. This study was done to address the unsettled therapeutic questions of administration schedule (alternate-day vs. daily administration) and dose (1 vs. 0.75 mg/kg) and to determine whether the duration of amphotericin B treatment in Bihar, India, can be shortened to 15 days.. Methods. To compare alternate-day versus daily administration and 1-mg/kg versus 0.75-mg/kg doses and to determine whether the duration of treatment could be abbreviated, Indian subjects randomly received 15 infusions of 1 mg/kg (group A; 245 patients) or 0.75 mg/kg (group B; 244 patients) on alternate days or 1 mg/kg (group C; 500 patients) or 0.75 mg/kg (group D; 496 patients) daily. Noninferiority testing ...http://oxfordindex.oup.com/view/10.1086/520665
Gene amplification in amphotericin B-resistant Leishmania tarentolae.
Two Leishmania tarentolae cells were selected step by step for resistance to the polyene antibiotic amphotericin B, a second-line drug against the parasite Leishmania. One of the mutants was cross-resistant to ketoconazole. DNA amplification was observed in both mutants. The amplicons were extrachromosomal circles and were derived from different chromosomes. In one mutant the circle was unusually stable as it remained within the cell despite numerous passages in the absence of the drug. A circumstantial link between the copy number of amplicons and the resistance levels was established. Gene transfection experiments indicated that the link between the locus amplified and the resistance levels was not straightforward and possibly several mutations act together to lead to amphotericin B resistance. Copyright 2001 Elsevier Science (USA).. ...http://www.ketoconazole.com/news_article.html?tx_ttnews%5Bpointer%5D=6&tx_ttnews%5Btt_news%5D=527&tx_ttnews%5BbackPid%5D=77&no_cache=1
Cryptococcosis | Pediatric OI Prevention and Treatment Guidelines | AIDSinfo
In patients who cannot tolerate flucytosine (or if flucytosine is not available), amphotericin B deoxycholate (or its liposomal preparation) with or without fluconazole can be used for initial therapy (BI*). In a randomized Phase II trial in HIV-infected adolescents and adults, amphotericin B deoxycholate plus high-dose fluconazole (800 mg daily) was found to be well tolerated and with a trend toward better outcome at days 42 and 70, compared with amphotericin B deoxycholate alone.25 Studies are needed to further validate the use of this combination. In another study 80 HIV-seropositive, antiretroviral (ARV)-naive adults presenting with cryptococcal meningitis were randomized to 4 treatment arms of 2-week duration: group 1, amphotericin B (0.7-1 mg/kg) and flucytosine (25 mg/kg 4 times daily); group 2, amphotericin B (0.7-1 mg/kg) and ...https://aidsinfo.nih.gov/guidelines/html/5/pediatric-oi-prevention-and-treatment-guidelines/400/cryptococcosis
Amphotericin B Lipid Complex injection 10,25,50 & 100 mg Supplier,Exporter ,Wholesaler Price India | 3S Corporation
It is used in the treatment of fungal infections. 3s corporation is Exporter ,Wholesaler for Amphotericin B Lipid Complex injection10,25,50 & 100 mg in India.http://www.3scorporation.com/products/amphotericin-b-lipid-complex-injection-102550-100-mg/
amphotericin B - WellSpan Health Library
Amphotericin B is an antifungal medication that fights infections caused by fungus. Amphotericin B is used to treat serious, life-threatening fungal infections. It is not for use in treating a minor fungal infection such as a yeast infection of the mouth, esophagus, or vagina. Amphotericin B may also be used for...https://www.wellspan.org/health-library/Document.aspx?id=d00077a1
The post antifungal effect of nystatin and amphotericin B on Candida Species in different media - UQ eSpace
Shu, M, Ellepola, ANB and Samaranayake, LP (2000). The post antifungal effect of nystatin and amphotericin B on Candida Species in different media. In: Journal of Dental Research. , , (479-479). . ...https://espace.library.uq.edu.au/view/UQ:322889
To Study the Effect Of Single Infusions Of Amphotericin B Lipid Preparations in Treatment of Patients Of Kala Azar - Full Text...
Visceral Leishmaniasis, which is progressive and fatal if not treated, is an insidious, chronic disease that is characterized by irregular fever, anorexia, weight loss, cough, gross enlargement of the spleen and liver, mild anemia and emaciation. This may be preceded by rigors and vomiting. If untreated, Kala-azar, which is the most severe form of Leishmaniasis, has a mortality rate of nearly 100%.. The goal of the project is to establish that a single dose of AMPHOMUL® can be used to achieve a Definitive cure for Visceral Leishmaniasis leading to a short course therapy. The project will also seek to establish that AMPHOMUL ® is safe, at least as effective and more affordable than current treatment, and is without the risk of drug resistance.. The trial is a Prospective, Multicentric, Randomized, Two Arm, Open label Phase III study to Assess Efficacy and Safety of Infusion of Amphomul® (Amphotericin B Emulsion) as Compared to Liposomal ...https://clinicaltrials.gov/ct2/show/NCT00876824
Safety and Efficacy of Liposomal Amphotericin B Compared with Conventional Amphotericin B for Induction Therapy of...
Note: This work was presented in part at the 7th Conference on Retroviruses and Opportunistic Infections, San Francisco, California, 31 January 2000.. Acknowledgments: The authors thank Deanne Fuller, Dr. Tom Davis, and Ann LeMonte for laboratory work; Estella C. Wheatley for preparation of the manuscript; and Cynthia R. Flanigan for help with the management of the data over the course of the clinical trial.. Grant Support: In part by a grant from the National Institute of Allergy and Infectious Diseases to the Mycoses Study Group (contract NO1-A1-15802) and by a grant from the National Center for Research Resources, General Clinical Research Center (contract MO1-RR02558) to participating centers, and by Gilead Sciences, Inc. (formerly NeXstar Pharmaceuticals).. Requests for Single Reprints: Philip C. Johnson, MD, University of Texas-Houston Medical School, Division of General Medicine, 6431 Fannin, MSB 1.122, Houston, TX 77030; e-mail, Philip.C.Johnson@uth.tmc.edu.. Current Author Addresses: ...http://annals.org/aim/fullarticle/715437/safety-efficacy-liposomal-amphotericin-b-compared-conventional-amphotericin-b-induction
amphotericin B deoxycholate loaded cubosomal nanoparticles mixture
Page contains details about amphotericin B deoxycholate loaded cubosomal nanoparticles mixture . It has composition images, properties, Characterization methods, synthesis, applications and reference articles : nano.nature.comhttp://nano.nature.com/nano/GR-M2849136
Biology-Online • View topic - The Fiber Disease
A Double-Blind, Randomized, Controlled Trial of Amphotericin B Colloidal Dispersion versus Amphotericin B for Treatment of Invasive Aspergillosis in Immunocompromised Patients [Bowden R et al. CID 2002;35:359]: The authors report a multicenter randomized, double-blind trial of Amphotec (ABCD) in a dose of 6 mg/kg/day vs. Amphotericin B in a dose of 1.0-1.5 mg/kg/day for treatment of invasive aspergillosis in 174 patients. The diagnosis was considered "proven" if there was a compatible clinical illness and detection of aspergillus by stain or culture from a normally sterile site, or proven with histopathology; it was "probable" if pulmonary with typical clinical and x-ray findings combined with two positive sputum cultures or a positive stain or culture from a BAL. Of the 174 participants, 88 were given ABCD and 86 were given Amphotericin B. Most of the patients had a ...http://www.biology-online.org/biology-forum/about1958-3744.html?hilit=Inlet
Amphotericin B | Pathway Medicine
Amphotericin B binds to ergosterol in the cell wall of fungi and generates pores which permeabilize the cell wall. Deranges permeability of the fungal cell wall, especially to electrolytes, probably results in fungal cell death. At higher concentrations Amphotericin B begins binding cholesterol in the mammalian cell membrane and accounts for the drug's adverse effects ...http://pathwaymedicine.org/Amphotericin-B
Search for AMPHOTERICIN B Within Specific Sites
Use Google powered SiteComber to search within various sites for AMPHOTERICIN B. Links to searches for AMPHOTERICIN B can be found here.http://sitecomber.com/s/AMPHOTERICIN-B
Safety, Efficacy, and Pharmacokinetics of Amphotericin B Lipid Complex - Full Text View - ClinicalTrials.gov
This is a randomized, open label, prospective study of ABLC at 5.0 and 10.0 mg/kg/d for treatment of patients with cryptococcal meningitis. Patients will be randomly assigned in a 1:1 ratio to receive 5.0 or 10.0 mg/kg/d of ABLC as induction therapy for cryptococcal meningitis. Patients receiving 10 mg/kg/d doses will be treated with ABLC for 7 days whereas patients receiving ABLC at 5.0 mg/kg/d will receive 14 days of ABLC therapy. After completion of induction therapy subjects will receive long-term fluconazole maintenance therapy at the discretion of the treating physician. The study will be conducted at the Washington Hospital ...https://clinicaltrials.gov/show/NCT01656382?order=132
Low-Dose Liposomal Amphotericin Effective in Aspergillosis | Cancer Network | The Oncology Journal
NEW ORLEANS-High doses of liposomal amphotericin B are no more effective than low doses in the treatment of invasive aspergillosis in neutropenic patients, European researchers reported at the Interscience Conference on Antimicrobial Agents and Chemotherapy. 1http://www.cancernetwork.com/articles/low-dose-liposomal-amphotericin-effective-aspergillosis
MK0991 Versus Amphotericin B for Empirical Therapy in Febrile, Neutropenic Pediatric Patients (0991-044) - Full Text View -...
This study is a double-blind, randomized study of MK0991 versus liposomal amphotericin B in the empirical treatment of pediatric patients (ages 2 through 17 years) who have an absolute neutrophil count (ANC) below 500/microliter and who have fever despite broad antibiotic coverage. Such patients would be candidates for empirical therapy with an intravenous anti-fungal agent ...https://clinicaltrials.gov/ct2/show/NCT00082537
IDEALS @ Illinois: Synthesis-enabled understanding of the mechanism of action of amphotericin B and the development of...
The polyene macrolide amphotericin B (AmB) remains a critically vital antifungal as the last line of defense against a wide range of life-threatening fungal pathogen. Despite its clinical usage for over half a century, AmB has evaded the development of clinically relevant microbial resistance. AmB has been shown to form ion channels similar to that of their protein counterparts, which has led to the proposal that AmB kills yeast cells via membrane permeabilization. The capacity for ion channel formation and cytotoxicity of AmB are thought to be dependent upon membranous sterol, but the role of sterols in this mechanism and whether membrane permeabilizaton and biological activity are even linked has remained unclear. Thus, the complete understanding of the mechanism of action of AmB would enable the development of new antifungals with an improved therapeutic index, as well as guide the pursuit of new antimicrobials that evade resistance. To elucidate the operative mechanism, ...https://www.ideals.illinois.edu/handle/2142/92874
Study to Compare the Efficacy and Safety of Micafungin Versus Conventional Amphotericin B for the Treatment of Neonatal...
Time to a positive clinical response is defined as the time from the first dose to the day during the treatment period that a positive clinical response (defined as a complete response or partial response) is observed for the first time, assessed by the Investigator.. Complete Response is defined as the resolution of all attributable signs related to fungal infection, if present at baseline and Partial Response is defined as improvement in attributable signs related to the fungal infection, if present at baseline.. Infants without positive responses and who survived were censored at one day post the end of treatment. Infants without positive responses who died before completing the treatment period, or were lost to follow-up during the treatment were censored at their death or last contact day. ...https://clinicaltrials.gov/ct2/show/study/NCT00815516
Study to Compare the Efficacy and Safety of Micafungin Versus Conventional Amphotericin B for the Treatment of Neonatal...
Time to a positive clinical response is defined as the time from the first dose to the day during the treatment period that a positive clinical response (defined as a complete response or partial response) is observed for the first time, assessed by the Investigator.. Complete Response is defined as the resolution of all attributable signs related to fungal infection, if present at baseline and Partial Response is defined as improvement in attributable signs related to the fungal infection, if present at baseline.. Infants without positive responses and who survived were censored at one day post the end of treatment. Infants without positive responses who died before completing the treatment period, or were lost to follow-up during the treatment were censored at their death or last contact day. ...https://clinicaltrials.gov/show/NCT00815516
A Comparison of Fluconazole and Amphotericin B in the Treatment of Fungal Infections - Full Text View - ClinicalTrials.gov
To compare the safety, tolerance and efficacy of fluconazole and amphotericin B as treatment for biopsy proven fungal infections in major organs, disseminated infection, suspected fungal infection and fungemia in adult neutropenic and non-neutropenic patients without AIDS, AIDS related complex (ARC), or extensive burns. HIV seropositive patients are allowed only if they also have a malignancy ...https://clinicaltrials.gov/show/NCT00002277?order=223